BioSyent

BioSyent Short-term Debt

The Short-Term Debt of BioSyent (RX.V) as of Oct 27, 2026 is 183,314.00 CAD. In the previous year, Short-Term Debt was 174,055.00 CAD — a change of 5.32% (higher).

Short-term Debt

183,314.00CAD

YoY

5.32%

Last updated:

Short-Term Debt of BioSyent is 2023 183,314.00 CAD. Short-Term Debt of BioSyent was 2022 174,055.00 CAD. It decreases by 5.32% higher compared to the previous year.

The BioSyent Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2019
144,253.00 CAD
Jan 1, 2020
151,949.00 CAD
Jan 1, 2021
161,809.00 CAD
Jan 1, 2022
174,055.00 CAD
Jan 1, 2023
183,314.00 CAD
The BioSyent Short-term Debt history
YEARShort-term DebtYoY
183,314.00CAD+5.32%
174,055.00CAD+7.57%
161,809.00CAD+6.49%
151,949.00CAD+5.34%
144,253.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

Short-Term Debt of BioSyent is 183,314.00 CAD in 2023.

Short-Term Debt of BioSyent changed from 174,055.00 CAD to 183,314.00 CAD, representing a 5.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt BioSyent since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's BioSyent historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioSyent

All Key Metrics — BioSyent